Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

Lilly is continuing with its goal of submitting for approval of orforglipron in obesity by the end of 2025, and in type 2 diabetes in 2026. Image credit: Tada Images / Shutterstock.com Eli Lilly’s ...

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

Eli Lilly announced the data from the OLE trial of Omvoh at United European Gastroenterology (UEG) Week in Berlin. Image credit: hapabapa / iStock Editorial via Getty Images Eli Lilly’s Omvoh ...

The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...

Enanta Pharmaceuticals reported that the Phase IIb trial failed to meet its primary endpoint. Image credit: viewimage / Shutterstock.com. Enanta Pharmaceuticals has seen its stock more than double, ...